MarketCap
Facebook
X
Telegram
Biogen Cost of Revenue | BIIB
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4 B | 2.31 B | 2.53 B | 2.28 B | 2.11 B | 1.81 B | 1.96 B | 1.82 B | 1.63 B | 1.48 B | - | - | - | 545 M | 467 M | 400 M | 382 M | 402 M | 335 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.53 B | 335 M | 1.43 B |
Quarterly Cost of Revenue Biogen
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 661 M | 674 M | 605 M | 629 M | 639 M | 546 M | 542 M | 660 M | 593 M | 663 M | - | 470 M | 484 M | 754 M | - | 512 M | 460 M | 938 M | - | 449 M | 411 M | 454 M | - | 430 M | 476 M | 602 M | - | 461 M | 421 M | 446 M | - | 370 M | 366 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 134 M | - | 139 M | 139 M | 133 M | - | 124 M | 101 M | 103 M | 95.9 M | 107 M | 97.1 M | 93.5 M | 90.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 938 M | 90.7 M | 412 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Silence Therapeutics plc
SLN
|
10.3 M | $ 10.14 | 0.78 % | $ 1.44 B |  Britain |
 |
SELLAS Life Sciences Group
SLS
|
100 K | $ 11.63 | 3.62 % | $ 1.27 B |  USA |
 |
Soligenix
SNGX
|
119 K | $ 0.36 | 0.6 % | $ 1.87 M | USA |
 |
Sanofi
SNY
|
13 B | $ 39.51 | 1.19 % | $ 48.2 B |  France |
 |
Sarepta Therapeutics
SRPT
|
25.5 M | $ 17.49 | 0.7 % | $ 1.75 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
74.6 M | $ 42.76 | 0.9 % | $ 2.41 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
889 K | $ 2.08 | 1.99 % | $ 1.41 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
1.58 T | $ 17.81 | 0.08 % | $ 28.1 B |  Japan |
 |
Bio-Techne Corporation
TECH
|
416 M | $ 72.58 | 0.25 % | $ 11.3 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
8.32 B | $ 39.66 | 0.33 % | $ 45.4 B |  Israel |
 |
TG Therapeutics
TGTX
|
101 M | $ 53.91 | 0.12 % | $ 7.78 B | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
6.64 M | $ 8.07 | 0.54 % | $ 68.7 M | USA |
 |
Taysha Gene Therapies
TSHA
|
47.7 M | $ 4.49 | 0.11 % | $ 1.44 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
12.4 M | $ 42.78 | 3.33 % | $ 2.06 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
384 M | $ 536.4 | 0.37 % | $ 23.8 B | USA |
 |
Vericel Corporation
VCEL
|
70.7 M | $ 41.07 | 2.29 % | $ 2.07 B | USA |
 |
Veracyte
VCYT
|
36.1 M | $ 47.67 | 4.06 % | $ 3.75 B | USA |
 |
Vir Biotechnology
VIR
|
26 K | $ 11.78 | 5.46 % | $ 1.63 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
13 M | $ 4.58 | 0.51 % | $ 270 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
2.6 M | $ 4.31 | 0.21 % | $ 45.9 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
1.65 B | $ 503.5 | 0.07 % | $ 129 B | USA |
 |
Verastem
VSTM
|
165 K | $ 8.0 | 3.9 % | $ 554 M | USA |
 |
Xenetic Biosciences
XBIO
|
44.8 K | $ 2.2 | 0.45 % | $ 3.74 M | USA |
|
XBiotech
XBIT
|
651 K | $ 2.18 | 0.23 % | $ 66.5 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
42.6 M | $ 10.13 | 11.56 % | $ 1.63 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
5.76 M | $ 2.9 | 2.47 % | $ 123 M | USA |
 |
22nd Century Group
XXII
|
10.2 M | $ 0.91 | 2.13 % | $ 168 K | USA |